Breakthroughs that
See news releases about Etira, our stellar team,
ERX-315-001 SITE INITIATION VISIT @TKCC
NewsSydney, Australia – September 4, 2024: The Etira team, led by Founder Dr. Ganesh Raj, and the clinical Contract Research Organization Novotech successfully performed the site initiation visit at the Kinghorn Cancer Center (TKCC) in Sydney…
ERX-315 CLINICAL TRIAL APPROVED BY HREC
NewsDallas, TX – August 1, 2024: Etira is pleased to announce the approval of the ERX-315 Phase 1 clinical trial by the Australian Human Research Ethics Committee (HREC). This HREC approval enables the start of the clinical trial titled "A Phase…
Etira’s Australian partner MMIC expands
NewsMelbourne, Australia - July 10, 2024: The expansion of Etira partner Medicines Manufacturing Innovation Centre (MMIC) to the Monash Technology Precinct in Clayton was highlighted in the press. This expansion will enable further opportunities…
DECRYPTING THE OLIGO-BENZAMIDE PLATFORM
NewsDallas, TX – June 15, 2024: The laboratory of Etira founder Dr Jung-Mo Ahn presents a comprehensive overview of the oligo-benzamide platform that emulates a-helical peptide segments in proteins and disrupts protein-protein interactions. Herein,…
ERX-315 SUBMITTED FOR HREC APPROVAL
NewsDallas, TX – May 14th, 2024: Etira is pleased to announce the submission of the regulatory documents for approval of administration of its breakthrough oncology drug ERX-315 to the Human Research Ethics Committee (HREC) in Australia. This…
Where to find us
Boston Office:
75 Kneeland Ave, 14th Floor
Boston. MA. 02111
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247